Clinical Cardiology Alert – September 1, 2014

September 1, 2014

• Is Left Atrial Appendage Occlusion with the Watchman Device a Reasonable Alternative to Anticoagulation with Warfarin?

  The goal of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy (PREVAIL) trial was to assess the safety and efficacy of left atrial appendage (LAA) occlusion for stroke prevention in patients with atrial fibrillation (AF) compared with long-term warfarin therapy

  Read more

• Is Less More? Transfemoral TAVR: The Minimalist Approach

  Since its initial FDA approval in November 2011, transcatheter aortic valve replacement (TAVR) has rapidly gained acceptance as a standard therapy in the United States.

  Read more

• Colchicine for Recurrent Pericarditis

  Although colchicine has been shown to be effective for the treatment of acute pericarditis and first recurrences, little information exists about its use in patients with multiple recurrences. Thus, Imazio et al reported on the results of the colchicine for recurrent pericarditis 2 (CORP-2) trial.

  Read more

• Angiotensin Receptor Blockers for Hypertension

  Angiotensin receptor blockers (ARBs) are often used as first-line therapy for the treatment of systemic hypertension because of their perceived efficacy and relatively low incidence of adverse effects.

  Read more

• Bioabsorbable Coronary Scaffolds: Promise and Peril

  Clinical outcomes from percutaneous coronary intervention (PCI) have steadily improved over time, with transitions from balloon angioplasty to bare-metal stenting, and more recently from first-generation drug-eluting stents (DES) to second- and third-generation designs.

  Read more

• Pharmacology Watch and Clinical Briefs in Primary Care Available Online

  The September 2014 issues of Pharmacology Watch and Clinical Briefs in Primary Care are now available exclusively by e-mail or online.

  Read more